Literature DB >> 10944429

Nitric oxide dysfunction in the pathophysiology of preeclampsia.

D T Lowe1.   

Abstract

Researchers disagree as to the importance of nitric oxide (NO) in preeclampsia. Many researchers have alluded to NO's possible primary or secondary role in the development of preeclampsia, but few have correlated the dysfunction of nitric oxide production with the other metabolic derangements seen in this condition. This paper will review the evidence that the primary dysfunction in preeclampsia is a relative deficiency of available NO (secondary to oxidative degradation) and an excess of peroxynitrite (ONOO(-)). The combination of a deficiency of NO and an increase in ONOO(-) can directly or indirectly initiate the vast majority of physiological and serological changes associated with preeclampsia, such as blood pressure, increased glomerular filtration rate, proteinuria, platelet dysfunction, increased thromboxane and endothelin, and a decrease in prostacyclin. Understanding the complex role of nitric oxide in this condition may explain why previous interventions have been unsuccessful and suggest possible strategies for prevention and treatment in the future. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10944429     DOI: 10.1006/niox.2000.0296

Source DB:  PubMed          Journal:  Nitric Oxide        ISSN: 1089-8603            Impact factor:   4.427


  32 in total

Review 1.  Preeclampsia: theories and speculations.

Authors:  Jeffrey C Livingston; Bryan D Maxwell
Journal:  Wien Klin Wochenschr       Date:  2003-03-31       Impact factor: 1.704

Review 2.  The future of endothelin-receptor antagonism as treatment for systemic hypertension.

Authors:  Gabriel Vorobiof; Burns C Blaxall; John D Bisognano
Journal:  Curr Hypertens Rep       Date:  2006-04       Impact factor: 5.369

Review 3.  The role of L-arginine in the prevention and treatment of pre-eclampsia: a systematic review of randomised trials.

Authors:  T Dorniak-Wall; R M Grivell; G A Dekker; W Hague; J M Dodd
Journal:  J Hum Hypertens       Date:  2013-10-31       Impact factor: 3.012

4.  Soluble fms-like tyrosine kinase 1 promotes angiotensin II sensitivity in preeclampsia.

Authors:  Suzanne D Burke; Zsuzsanna K Zsengellér; Eliyahu V Khankin; Agnes S Lo; Augustine Rajakumar; Jennifer J DuPont; Amy McCurley; Mary E Moss; Dongsheng Zhang; Christopher D Clark; Alice Wang; Ellen W Seely; Peter M Kang; Isaac E Stillman; Iris Z Jaffe; S Ananth Karumanchi
Journal:  J Clin Invest       Date:  2016-06-06       Impact factor: 14.808

5.  Comment on Dorniak-Wall et al.'s paper on L-arginine for pre-eclampsia.

Authors:  D T Lowe
Journal:  J Hum Hypertens       Date:  2014-01-16       Impact factor: 3.012

6.  Glyceryl trinitrate inhibits hypoxia-induced release of soluble fms-like tyrosine kinase-1 and endoglin from placental tissues.

Authors:  Ivraym B Barsoum; Stephen J Renaud; Charles H Graham
Journal:  Am J Pathol       Date:  2011-06       Impact factor: 4.307

7.  Sildenafil Prevents Apoptosis of Human First-Trimester Trophoblast Cells Exposed to Oxidative Stress: Possible Role for Nitric Oxide Activation of 3',5'-cyclic Guanosine Monophosphate Signaling.

Authors:  Jay M Bolnick; Brian A Kilburn; Alan D Bolnick; Michael P Diamond; Manvinder Singh; Michael Hertz; Jing Dai; D Randall Armant
Journal:  Reprod Sci       Date:  2014-11-26       Impact factor: 3.060

Review 8.  Drug treatment of hypertension in pregnancy.

Authors:  Catherine M Brown; Vesna D Garovic
Journal:  Drugs       Date:  2014-03       Impact factor: 9.546

9.  Effect of rosuvastatin on arginase enzyme activity and polyamine production in experimental breast cancer.

Authors:  Hakan Erbaş; Oğuz Bal; Erol Çakır
Journal:  Balkan Med J       Date:  2015-01-01       Impact factor: 2.021

Review 10.  Preeclampsia: Updates in Pathogenesis, Definitions, and Guidelines.

Authors:  Elizabeth Phipps; Devika Prasanna; Wunnie Brima; Belinda Jim
Journal:  Clin J Am Soc Nephrol       Date:  2016-04-19       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.